Investigational drug · Phase 2
Mizagliflozin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Postbariatric Hypoglycemia.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Mizagliflozin"
First trial start
2026
Oct 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mizagliflozin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postbariatric Hypoglycemia
Largest trials
Live from ClinicalTrials.gov: studies naming "Mizagliflozin" as an intervention, largest first.
Vogenx, Inc.Industry
NCT07760961 · 36 participants (planned) · Start Oct 20, 2026 · Primary completion Oct 2027
Drug: Mizagliflozin 5 mg; Mizagliflozin 10 mg and 1 more · For: Postbariatric Hypoglycemia
Sites: Chula Vista, California; Palo Alto, California; Aurora, Colorado · 11 sites in all
- Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsCompleted
Vogenx, Inc.Industry
NCT05721729 · 15 participants · Start Jun 23, 2023 · Primary completion May 1, 2024
Drug: Mizagliflozin; Placebo · For: Postbariatric Hypoglycemia
Sites: Palo Alto, California; Aurora, Colorado
- Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia SubjectsCompleted
Vogenx, Inc.Industry
NCT05541939 · 9 participants · Start Sep 13, 2022 · Primary completion Feb 17, 2023
Drug: Mizagliflozin · For: Postbariatric Hypoglycemia
Sites: Palo Alto, California; Aurora, Colorado
Newest research
PubMed records naming it or its code names, newest first.
- Sodium-glucose cotransporter 1 exacerbates colon cancer malignancy by suppressing ferroptosis via the Nrf2/HO-1/SLC7A11/GPX4 axis under high glucose conditions.
Lin Y, Zheng X, Zhou Q, et al. · Arch Biochem Biophys 2026
- A single dose trial of mizagliflozin for the treatment of postbariatric hypoglycemia.
Lawler HM, McLaughlin TL, Shakeri S, et al. · J Endocr Soc 2026
- Dysfunctional glucose metabolism triggers oxidative stress to induce kidney injury in diabetes.
Gao M, Dai MT, Gong GH · World J Diabetes 2025
- Mizagliflozin ameliorates diabetes induced kidney injury by inhibitor inhibit inflammation and oxidative stress.
Lin ZM, Gao HY, Shi SH, et al. · World J Diabetes 2025
- Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation.
Forrester EA, Benítez-Angeles M, Redford KE, et al. · Cardiovasc Res 2024
- Sodium-dependent glucose co-transport proteins (SGLTs) are not involved in human glucose taste detection.
Palmer RK, Nechiporenko AB, Ilies MA, et al. · PLoS One 2024
Also in development for Postbariatric Hypoglycemia
- INN imapextideMBX 1416Phase 21 trial
MBX Biosciences · Postbariatric Hypoglycemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.